[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Taysha Gene Therapies Inc (TSHA)

Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,821,869
  • Shares Outstanding, K 287,361
  • Annual Sales, $ 9,770 K
  • Annual Income, $ -109,000 K
  • EBIT $ -110 M
  • EBITDA $ -109 M
  • 60-Month Beta 1.19
  • Price/Sales 186.42
  • Price/Cash Flow N/A
  • Price/Book 8.42

Options Overview Details

View History
  • Implied Volatility 115.90% (+3.42%)
  • Historical Volatility 69.96%
  • IV Percentile 41%
  • IV Rank 25.59%
  • IV High 245.50% on 03/03/26
  • IV Low 71.32% on 08/20/25
  • Expected Move (DTE 18) 1.29 (20.38%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 732
  • Volume Avg (30-Day) 945
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 26,854
  • Open Int (30-Day) 25,060
  • Expected Range 5.05 to 7.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 3
  • High Estimate $-0.11
  • Low Estimate $-0.12
  • Prior Year $-0.09
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.26 +20.65%
on 06/09/26
7.06 -10.20%
on 06/24/26
+0.75 (+13.42%)
since 05/26/26
3-Month
4.03 +57.32%
on 03/30/26
7.30 -13.15%
on 05/06/26
+2.02 (+46.76%)
since 03/26/26
52-Week
2.25 +181.78%
on 07/01/25
7.30 -13.15%
on 05/06/26
+3.93 (+163.07%)
since 06/26/25

Most Recent Stories

More News
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting

Recently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through ≥12 months post-TSHA-102 regardless of age or disease severity ...

TSHA : 6.34 (+2.09%)
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...

TSHA : 6.34 (+2.09%)
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...

TSHA : 6.34 (+2.09%)
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6 ‑ month interim analysis and FDA feedback on next steps toward BLA submission pathway expected 1H 2027 TSHA-102 was...

TSHA : 6.34 (+2.09%)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...

TSHA : 6.34 (+2.09%)
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recent...

TSHA : 6.34 (+2.09%)
Can Taysha Gene Therapies Finally Turn Rett Syndrome Data Into a Rerating Moment?

Barchart Research What to Expect from TSHA Earnings TSHA Generated May 5, 2026 Current Price $6.94 EPS Estimate $$-0.10 Consensus Rating Strong Buy Average Move 7.01% Can Taysha Gene Therapies Finally...

TSHA : 6.34 (+2.09%)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, May 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...

TSHA : 6.34 (+2.09%)
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...

TSHA : 6.34 (+2.09%)
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102...

TSHA : 6.34 (+2.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104...

See More

Key Turning Points

3rd Resistance Point 6.85
2nd Resistance Point 6.65
1st Resistance Point 6.50
Last Price 6.34
1st Support Level 6.14
2nd Support Level 5.94
3rd Support Level 5.79

See More

52-Week High 7.30
Last Price 6.34
Fibonacci 61.8% 5.37
Fibonacci 50% 4.78
Fibonacci 38.2% 4.18
52-Week Low 2.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.